MD-1 Inhibitors
Chemical inhibitors of MD-1 utilize various mechanisms to impede the function of this protein within immune signaling pathways. BAY 11-7082, Parthenolide, and Wedelolactone exert their inhibitory effects by targeting the NF-κB pathway, which is integrally connected with the functional activity of MD-1. BAY 11-7082 specifically inhibits the phosphorylation of IκBα, a precursor event to the activation of NF-κB. Similarly, Parthenolide suppresses NF-κB by directly targeting and inhibiting this transcription factor, while Wedelolactone acts as an inhibitor of IκB kinase, a key enzyme in the phosphorylation process that activates NF-κB. Emodin and Andrographolide also contribute to the inhibition of NF-κB, with Emodin interfering with the kinase activity of IκB and Andrographolide inhibiting NF-κB activation by modifying cysteine residues in its activation pathway.
In conjunction with these, SN50, PDTC, QNZ (EVP4593), TPCA-1, JSH-23, IMD-0354, and Sulforaphane constitute a group of inhibitors that prevent the activation and nuclear translocation of NF-κB, which is a critical step for MD-1 to exert its role in immune responses. SN50 contains a peptide sequence that impedes the nuclear translocation of activated NF-κB. PDTC blocks the oxidative modification of IκB, thereby preventing the degradation that would otherwise lead to NF-κB activation. QNZ stops NF-κB's translocation to the nucleus and its subsequent transcriptional activity. TPCA-1 selectively inhibits IκB kinase-2, crucial for IκB degradation. JSH-23 restricts NF-κB from entering the nucleus and binding to DNA, IMD-0354 inhibits IκB kinase, and Sulforaphane blocks the degradation of IκB. These diverse chemical actions converge on the common outcome of inhibiting NF-κB, thereby reducing the functional activity of MD-1 in immune signaling cascades.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Inhibits IκBα phosphorylation, thereby preventing activation of NF-κB, which is involved in the signaling pathways of MD-1. By inhibiting NF-κB, BAY 11-7082 reduces the functional activity of MD-1 which relies on NF-κB signaling for initiating immune responses. | ||||||
Parthenolide | 20554-84-1 | sc-3523 sc-3523A | 50 mg 250 mg | $79.00 $300.00 | 32 | |
Targets and inhibits NF-κB, a transcription factor that regulates the expression of genes critical to the immune response in which MD-1 is involved. By inhibiting NF-κB, Parthenolide suppresses the signaling cascade that MD-1 is a part of, thus inhibiting MD-1's function in the immune response. | ||||||
Wedelolactone | 524-12-9 | sc-200648 sc-200648A | 1 mg 5 mg | $108.00 $330.00 | 8 | |
Acts as an inhibitor of IκB kinase, which is essential for the activation of NF-κB. By inhibiting this kinase, Wedelolactone impairs the NF-κB pathway, resulting in the inhibition of downstream immune responses in which MD-1 is involved. | ||||||
Emodin | 518-82-1 | sc-202601 sc-202601A sc-202601B | 50 mg 250 mg 15 g | $103.00 $210.00 $6132.00 | 2 | |
Interferes with the kinase activity of IκB, leading to the inhibition of NF-κB. Since NF-κB is crucial for the signaling mechanisms that involve MD-1, blocking this pathway inhibits the functional role of MD-1 in immune response modulation. | ||||||
Andrographolide | 5508-58-7 | sc-205594 sc-205594A | 50 mg 100 mg | $15.00 $39.00 | 7 | |
Inhibits NF-κB activation by covalently modifying cysteine residues in the NF-κB activation pathway. This blockade prevents the transcription of NF-κB-dependent genes, thereby inhibiting the signaling pathways that are essential for MD-1's function in the immune response. | ||||||
Pyrrolidinedithiocarbamic acid ammonium salt | 5108-96-3 | sc-203224 sc-203224A | 5 g 25 g | $32.00 $63.00 | 11 | |
Pyrrolidine dithiocarbamate (PDTC) acts as an inhibitor of NF-κB by blocking the oxidation of IκB, which would otherwise lead to its degradation and subsequent activation of NF-κB. By inhibiting NF-κB, PDTC can inhibit the functional activity of MD-1, which relies on NF-κB for its role in immune signaling pathways. | ||||||
QNZ | 545380-34-5 | sc-200675 | 1 mg | $115.00 | 12 | |
Inhibits the activation of NF-κB by preventing its translocation to the nucleus and the subsequent transcription of immune response genes. As MD-1 functions within the NF-κB signaling pathway, inhibition of NF-κB by QNZ leads to a direct inhibition of MD-1's role in the immune response. | ||||||
IKK-2 Inhibitor IV | 507475-17-4 | sc-203083 | 500 µg | $130.00 | 12 | |
Selectively inhibits IκB kinase-2 (IKK-2), which is responsible for IκB degradation and NF-κB activation. By inhibiting IKK-2, TPCA-1 suppresses NF-κB signaling, thereby inhibiting the immune signaling pathways that involve MD-1. | ||||||
NFκB Activation Inhibitor II, JSH-23 | 749886-87-1 | sc-222061 sc-222061C sc-222061A sc-222061B | 5 mg 10 mg 50 mg 100 mg | $210.00 $252.00 $1740.00 $1964.00 | 34 | |
Blocks the nuclear translocation of NF-κB and inhibits its DNA binding activity. As MD-1 is implicated in immune signaling pathways that require NF-κB activity, JSH-23 effectively inhibits MD-1's function by disrupting the NF-κB pathway. | ||||||
IMD 0354 | 978-62-1 | sc-203084 | 5 mg | $199.00 | 3 | |
Inhibits IκB kinase, thereby preventing NF-κB activation. Since MD-1 is part of the signaling pathways regulated by NF-κB, IMD-0354's inhibition of IκB kinase results in functional inhibition of MD-1 by hindering the downstream immune response signaling. | ||||||